ARE BIOMARKERS A BIG MARKET ACCESS BONUS? US AND EU5 PAYER PERSPECTIVES AND PRESCRIBING PATTERNS FOR KEY TARGETED NON-SMALL-CELL LUNG CANCER AGENTS
Author(s)
Cox J1, Roberts D1, Gheorghe D1, Moore R2
1Decision Resources Group, London, UK, 2Decision Resources Group, Nashville, TN, USA
Presentation Documents
OBJECTIVES: Biomarker-driven prescribing is potentially highly cost-effective as it directs premium-priced treatment towards most-likely responders. As competition intensifies and collective treatment costs rise, however, this study examined the US and EU5 reimbursement and prescribing landscape for personalized medicines, focusing on non-small-cell lung cancer (NSCLC).
METHODS:
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PCN135
Topic
Economic Evaluation, Health Policy & Regulatory, Health Service Delivery & Process of Care, Health Technology Assessment
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Decision & Deliberative Processes, Health Disparities & Equity, Hospital and Clinical Practices, Prescribing Behavior, Pricing Policy & Schemes, Reimbursement & Access Policy, Treatment Patterns and Guidelines
Disease
Oncology
Explore Related HEOR by Topic